Lunai Bioworks is a pre-clinical stage biotechnology and healthcare AI company with no approved products and no commercial revenue. Lunai operates through three subsidiaries. Renovaro Biosciences is developing allogeneic dendritic cell therapeutic vaccines aimed at inducing remission in hard-to-treat solid tumors, including pancreatic cancer and triple-negative breast cancer. The therapy uses "off-the-shelf" donor cells to train the immune system to recognize and destroy cancer cells, rather than cells derived from each individual patient. The lead program has completed pre-IND work but has not entered human trials. Renovaro Cube is developing an AI platform for early cancer detection and treatment selection, analyzing liquid biopsy blood samples using a multi-omics approach to detect cancer signals in asymptomatic patients. Renovaro Cube's near-term plan is to operate certified labs performing liquid biopsy sequencing for research and academic clients, while collecting data to improve its AI platform, with longer-term plans to sell diagnostic software and test kits to hospitals, clinics, and pharma companies. BioSymetrics, acquired in April 2025, is a B2B AI platform focused on drug discovery and biomarker identification, integrating multi-modal biomedical data and using zebrafish models for high-throughput drug screening, targeting pharma and biotech companies as customers. All three businesses are pre-revenue and require substantial additional investment. Lunai funds operations through capital raises and has flagged going-concern risk.